Anaita Kanga-Parabia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anaita Kanga-Parabia has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Ainsley Janelle Newson
The University of Sydney
1 shared publication - Alison Dalton Archibald
Department of Paediatrics, The University of Melbourne, Parkville, Australia
1 shared publication - Belinda J. McClaren
Murdoch Children’s Research Institute, Melbourne, Australia
1 shared publication - Bruce Bennetts
Sydney Genome Diagnostics, Western Sydney Genetics Program, Sydney Children’s Hospitals Network, Westmead, NSW 2145, Australia
1 shared publication - Corrina C. Cliffe
NSW Health Pathology Randwick Genomics Laboratory, Randwick, NSW 2031, Australia
1 shared publication - Edwin Philip Kirk
Genomics Laboratory New South Wales Health Pathology Randwick New South Wales Australia
1 shared publication
Latest Publications
- Open Access
- 28 October 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (11) , 1781
The Australian Reproductive Genetic Carrier Screening Project (Mackenzie’s Mission): Design and Implementation
Reproductive genetic carrier screening (RGCS) provides people with information about their chance of having children with autosomal recessive or X-linked genetic conditions, enabling informed reproductive decision-making. RGCS is recommended to be offered to all couples during preconception or in early pregnancy. However, cost and a lack of awareness may prevent access. To address this, the Australian Government funded Mackenzie’s Mission—the Australian Reproductive Genetic Carrier Screening Project. Mackenzie’s Mission aims to assess the acceptability and feasibility of an easily accessible RGCS program, provided free of charge to the participant. In study Phase 1, implementation needs were mapped, and key study elements were developed. In Phase 2, RGCS is being offered by healthcare providers educated by the study team. Reproductive couples who provide consent are screened for over 1200 genes associated with >750 serious, childhood-onset genetic conditions. Those with an increased chance result are provided comprehensive genetic counseling support. Reproductive couples, recruiting healthcare providers, and study team members are also invited to complete surveys and/or interviews. In Phase 3, a mixed-methods analysis will be undertaken to assess the program outcomes, psychosocial implications and implementation considerations alongside an ongoing bioethical analysis and a health economic evaluation. Findings will inform the implementation of an ethically robust RGCS program.
- 28 October 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (11) , 1781
Open AccessThe Australian Reproductive Genetic Carrier Screening Project (Mackenzie’s Mission): Design and Implementation
Reproductive genetic carrier screening (RGCS) provides people with information about their chance of having children with autosomal recessive or X-linked genetic conditions, enabling informed reproductive decision-making. RGCS is recommended to be offered to all couples during preconception or in early pregnancy. However, cost and a lack of awareness may prevent access. To address this, the Australian Government funded Mackenzie’s Mission—the Australian Reproductive Genetic Carrier Screening Project. Mackenzie’s Mission aims to assess the acceptability and feasibility of an easily accessible RGCS program, provided free of charge to the participant. In study Phase 1, implementation needs were mapped, and key study elements were developed. In Phase 2, RGCS is being offered by healthcare providers educated by the study team. Reproductive couples who provide consent are screened for over 1200 genes associated with >750 serious, childhood-onset genetic conditions. Those with an increased chance result are provided comprehensive genetic counseling support. Reproductive couples, recruiting healthcare providers, and study team members are also invited to complete surveys and/or interviews. In Phase 3, a mixed-methods analysis will be undertaken to assess the program outcomes, psychosocial implications and implementation considerations alongside an ongoing bioethical analysis and a health economic evaluation. Findings will inform the implementation of an ethically robust RGCS program.